ICLE 2026 will showcase the most recent scientific advancements in lymphocyte engineering. It will also explore how these new findings can be used in the real world of medicine.
Take a look at the highlights below to learn more about what will be covered.
REAL-WORLD EXPERIENCE, NOVEL CLINICAL APPROACHES AND COMBINATION THERAPIES
SUPERPOWERED
LYMPHOCYTES
Learn more about engineering of lymphocytes for the co-expression of varied immune effectors in addition to the transgenic receptor.
NON-VIRAL CAR/TCR GENE TARGETING
Recent advancement in promoting integrations into lymphocyte genomes by means of nucleases or transposons.
CAR/TCR MRNA
THERAPIES
Exploring the therapeutic effects of transient CAR/TCR expression using mRNA delivery.
IN VIVO LYMPHOCYTE ENGINEERING
Explores emerging technologies that enable precise genetic modification of lymphocytes directly within the body to simplify and broaden therapeutic application.
HSC genetic engineering and epitope editing
Highlights advances in editing hematopoietic stem cells to create durable immune lineages with tailored antigens or tailored receptors.
BEYOND ALPHA-BETA
T CELLS
Discuss the engineering of alternative leukocytes including Gamma-Delta T cells, iNKT cells, NK cells, B cells and macrophages.
ADVANCED TCR
ENGINEERING
Targeting of non-malignant diseases, including infectious diseases, auto-immune diseases, cardiovascular diseases, genetic disorders and more.
TARGETING AUTOIMMUNE DISEASES
Examines how engineered lymphocytes can be designed to restore immune balance and counteract the pathological responses underlying autoimmune conditions.
